Viracta Therapeutics Q3 EPS $(0.33) Misses $(0.30) Estimate
Portfolio Pulse from Benzinga Newsdesk
Viracta Therapeutics reported Q3 losses of $(0.33) per share, missing the analyst consensus estimate of $(0.30) by 10 percent. However, this is a 29.79 percent improvement over losses of $(0.47) per share from the same period last year.
November 09, 2023 | 1:37 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Viracta Therapeutics' Q3 earnings per share missed estimates, which could negatively impact the stock price in the short term. However, the YoY improvement might mitigate this effect.
Earnings reports are a key indicator of a company's financial health. Missing estimates can lead to a decrease in stock price. However, the year-over-year improvement indicates a positive trend, which might soften the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100